Weight Loss · Lisle, IL

Tirzepatide for Weight Loss in Lisle, IL

Medically supervised tirzepatide protocols, prescribed and monitored by our clinical team. Custom dosing, weekly check-ins, real accountability.

Book a Free Consultation

What Is Tirzepatide?

Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved for chronic weight management and type 2 diabetes. It is administered as a once-weekly subcutaneous injection.

Generic name	Tirzepatide
FDA approval (weight loss)	November 2023
Mechanism	Dual GIP / GLP-1 receptor agonist
Administration	Once-weekly subcutaneous injection
Typical dose range	2.5 mg to 15 mg (titrated over months)

The Science

How Tirzepatide Works

Dual hormone activation

Tirzepatide activates two hormone receptors involved in appetite and blood sugar regulation: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1).

Reduced appetite

The combined GIP/GLP-1 signal acts on the brain to reduce hunger and food cravings. Most patients report eating significantly less without consciously trying.

Slower gastric emptying

Tirzepatide slows the rate at which the stomach empties, which increases the feeling of fullness after meals and helps stabilize blood sugar between meals.

Improved insulin sensitivity

By activating both incretin pathways, tirzepatide improves how the body responds to insulin. This is part of why it produces stronger metabolic results than GLP-1-only medications.

Clinical Research

What Research Shows About Tirzepatide

In the SURMOUNT-1 trial (published in the New England Journal of Medicine, 2022), adults with obesity who took 15 mg tirzepatide weekly lost an average of 22.5% of their body weight over 72 weeks. The 10 mg dose produced an average of 21.4%, and the 5 mg dose produced 16.0%.

For comparison, the highest semaglutide dose (2.4 mg) produced an average weight loss of approximately 15% in the STEP-1 trial. Tirzepatide also showed improvements in blood pressure, cholesterol, blood glucose, and waist circumference in trial participants.

Follow-up data from the SURMOUNT-4 trial suggested that continued tirzepatide treatment is needed to maintain weight loss; patients who discontinued treatment regained a significant portion of lost weight over 12 months.

Side-by-Side

Tirzepatide vs Semaglutide

Tirzepatide and semaglutide are the two most prescribed GLP-1 weight loss medications. Both are once-weekly injections, but their mechanisms and efficacy differ.

	Tirzepatide	Semaglutide
Mechanism	Dual GIP / GLP-1 agonist	GLP-1 agonist only
Average weight loss (highest dose)	~22.5%	~15%
FDA approval (weight loss)	2023	2021
Administration	Weekly injection	Weekly injection

Learn about semaglutide →

Our Program

How tirzepatide works at Defiant.

Free Consultation

Meet with our medical team to discuss your goals, medical history, and whether tirzepatide is right for you. No commitment.

Labs & Body Scan

Bring recent bloodwork from your PCP or Rythm Health. We review your labs and run a 3D body composition scan to establish your starting baseline.

Bi-Weekly Titration

Personalized tirzepatide dosing with titration every two weeks — faster and more responsive than the monthly schedules most brands use. Adjusted around your labs, body composition, and response.

Ongoing Support

Weekly nurse check-ins, monthly body composition scans, and real-time dose adjustments as you progress.

Pricing

Custom GLP-1 Protocols from $295/mo

Includes medication, provider oversight, weekly nurse check-ins, and monthly body composition scans. Defiant members save 20%.

Book Your Consultation

Good Candidates

Who Tirzepatide Is For

+ Adults with a BMI of 30 or higher
+ Adults with a BMI of 27 or higher with at least one weight-related condition (high blood pressure, type 2 diabetes, sleep apnea, cardiovascular disease)
+ People who have tried lifestyle changes without sustained results
+ Adults dealing with chronic inflammation or metabolic dysfunction — not just weight loss
+ People who are committed to lifestyle support alongside medication

Contraindications

Who Tirzepatide Is Not For

− Pregnant or breastfeeding individuals
− Personal or family history of medullary thyroid carcinoma
− Multiple endocrine neoplasia syndrome type 2 (MEN-2)
− Severe gastrointestinal disease, including gastroparesis
− Active pancreatitis or history of pancreatitis

Our medical team reviews your full history before prescribing. This is not an exhaustive list of contraindications.

FAQ

Tirzepatide Questions

Plain-language answers to the most common questions about tirzepatide treatment at Defiant in Lisle, IL.

Tirzepatide is a prescription medication FDA-approved for chronic weight management and type 2 diabetes. It is a dual GIP and GLP-1 receptor agonist, administered as a once-weekly subcutaneous injection.

The main difference is mechanism. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. In head-to-head clinical research, tirzepatide has produced greater average weight loss (22.5% at the highest dose) than semaglutide (about 15% at its highest dose).

In the SURMOUNT-1 trial, participants on the highest dose (15 mg weekly) lost an average of 22.5% of their body weight over 72 weeks. Individual results vary based on dose, duration, lifestyle factors, and adherence. Most people see meaningful weight loss within the first 12 weeks of treatment.

The most common side effects are gastrointestinal: nausea, diarrhea, constipation, vomiting, and reduced appetite. These are usually mild to moderate and most common during dose escalation. Serious but rare side effects include pancreatitis, gallbladder issues, and severe gastrointestinal events. Tirzepatide carries a boxed warning for thyroid C-cell tumors.

Most patients see meaningful appetite suppression within the first 1 to 2 weeks. Visible weight loss typically begins within the first month. Significant weight loss typically takes 3 to 6 months of consistent use, with continued progress over 12 to 18 months in clinical trials.

Yes. Tirzepatide is a prescription-only medication. At Defiant Health, our medical team evaluates whether tirzepatide is appropriate for you based on your recent bloodwork (from your PCP or Rythm Health), body composition, medical history, and goals.

Our Custom GLP-1 Protocols, including tirzepatide, start at $295 per month. Defiant members save 20%. Pricing includes the medication, provider oversight, weekly nurse check-ins, and monthly body composition scans.

Research from the SURMOUNT-4 trial suggests that most people regain a significant portion of lost weight after stopping tirzepatide. For long-term weight management, ongoing treatment combined with lifestyle support is typically required. Our team can discuss long-term protocol strategies during your consultation.

Defiant Health offers tirzepatide weight loss programs at our clinic in Lisle, IL, serving Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and the greater Chicago western suburbs. Book a free consultation to determine if tirzepatide is right for you.

Serving Naperville

Tirzepatide for Naperville Patients

Defiant Health’s clinic in Lisle sits just off I-88 and Route 53, a short drive from Naperville. A large share of our tirzepatide patients come from Naperville and the surrounding 60540, 60563, 60564, and 60565 ZIP codes.

Naperville patients on tirzepatide get the same medically supervised protocol that anchors all our weight loss care: bloodwork before your first dose, Styku body composition scans every four weeks, bi-weekly titration check-ins, and a dose curve built around how your body responds to the GIP/GLP-1 dual agonist, not a fixed package.

We treat tirzepatide patients from across the western suburbs too. Downers Grove sits just east of our Lisle clinic. Wheaton patients are a short drive north, and Bolingbrook residents reach us easily from the south. We also serve Lombard and the greater Chicago western suburbs.

Programs start at $295/month and include medication, provider oversight, and ongoing nurse access. Free consultations are available in-clinic or virtually for Naperville and western-suburb residents.

Get Started

Tirzepatide Weight Loss in Chicago’s Western Suburbs

Defiant Health offers tirzepatide weight loss programs at our Lisle, IL clinic, serving Naperville, Downers Grove, Wheaton, Bolingbrook, Lombard, and the greater Chicago western suburbs.